AVE-<wbr/>1625

AVE-1625

CAT N°: 10009021
Price:

From 92.00 78.20

The central cannabinoid (CB1) receptor is a G protein-coupled receptor that is widely distributed in the central nervous system and several peripheral tissues and binds the active component of cannabis, ?9-tetrahydrocannabinol.{6749} Signaling through the CB1 receptor is implicated in attentional and working memory deficits as well as obesity.{12559,14939,15542} AVE-1625 is a highly potent, selective antagonist for the CB1 receptor with Ki values of 0.16-0.44 nM.{15542} At 1-3 mg/kg, AVE-1625 significantly improves the performance of rodents in working memory tasks.{15542} At 30 mg/kg, AVE-1625 reduces caloric intake by more than 50% of controls and significantly increases lipolysis from fat tissues and reduces hepatic glycogen levels in rodents.{15541}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)-methanesulfonamide
  • Correlated keywords
    • cannabinoids CB1 receptors schizophrenia parkinsons disease alzheimers disease metabolism obesity SR-141716 lipolysis glycogenolysis antagonist endocrinology neurochemistry
  • Product Overview:
    The central cannabinoid (CB1) receptor is a G protein-coupled receptor that is widely distributed in the central nervous system and several peripheral tissues and binds the active component of cannabis, ?9-tetrahydrocannabinol.{6749} Signaling through the CB1 receptor is implicated in attentional and working memory deficits as well as obesity.{12559,14939,15542} AVE-1625 is a highly potent, selective antagonist for the CB1 receptor with Ki values of 0.16-0.44 nM.{15542} At 1-3 mg/kg, AVE-1625 significantly improves the performance of rodents in working memory tasks.{15542} At 30 mg/kg, AVE-1625 reduces caloric intake by more than 50% of controls and significantly increases lipolysis from fat tissues and reduces hepatic glycogen levels in rodents.{15541}

We also advise you